Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
- Conditions
- OsteoporosisHip Fracture
- Registration Number
- NCT00046254
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2127
- Male or female ages 50 years or older
- Must have a recent hip fracture repair in the past 90 days
- Must be able to walk with or without assistive device (for example, using a walker) prior to the hip fracture
- Current bisphosphonate users such as aredia (pamidronate), didronel (etidronate), fosamax (alendronate), actonel (residronate), skelid (tiludronate)
Other protocol-defined inclusion/exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Significant reduction in rate of clinical fractures after surgical repair of hip fracture
- Secondary Outcome Measures
Name Time Method Increase in total hip and femoral neck BMDs
Trial Locations
- Locations (28)
Novartis
馃嚛馃嚜Nuernberg, Germany
Radiant Research Lake Worth
馃嚭馃嚫Lake Worth, Florida, United States
University of Wisconsin Hospital and Clinics
馃嚭馃嚫Madison, Wisconsin, United States
University of Alabama Hospital
馃嚭馃嚫Birmingham, Alabama, United States
Galesburg Orthopedic Services LTD
馃嚭馃嚫Galesburg, Illinois, United States
Maine Medical Center Research Institute
馃嚭馃嚫Portland, Maine, United States
University of Maryland School of Medicine
馃嚭馃嚫Baltimore, Maryland, United States
Wayne State University, Div. of Endocrinology
馃嚭馃嚫Detroit, Michigan, United States
University of Pennsylvania Health System-Presbyterian Medical Center
馃嚭馃嚫Philadelphia, Pennsylvania, United States
Health East Osteoporosis Service
馃嚭馃嚫Woodbury, Minnesota, United States
Duke University Health System
馃嚭馃嚫Durham, North Carolina, United States
Ohio State University
馃嚭馃嚫Columbus, Ohio, United States
Palmetto Richland Memorial Hospital
馃嚭馃嚫Columbia, South Carolina, United States
St. Luke's Episcopal Hospital
馃嚭馃嚫Houston, Texas, United States
Sharp Grossmont Hosptial
馃嚭馃嚫La Mesa, California, United States
Illinois Bone and Joint Institute
馃嚭馃嚫Morton Grove, Illinois, United States
Mercy Arthritis and Osteoporosis Center
馃嚭馃嚫Des Moines, Iowa, United States
The Permanente Group
馃嚭馃嚫Santa Rosa, California, United States
Atlanta Resarch Center
馃嚭馃嚫Decatur, Georgia, United States
United Osteoporosis Center Health Services
馃嚭馃嚫Gainesville, Georgia, United States
Osteoporosis Diagnostic Center
馃嚭馃嚫Eureka, California, United States
University Orthopaedics
馃嚭馃嚫Canfield, Ohio, United States
Highland Hospital
馃嚭馃嚫Rochester, New York, United States
University of North Carolina Hospital
馃嚭馃嚫Chapel Hill, North Carolina, United States
Saint Joseph Medical Center
馃嚭馃嚫West Reading, Pennsylvania, United States
Saint Josephs
馃嚭馃嚫Warwick, Rhode Island, United States
Seton Medical Center
馃嚭馃嚫Austin, Texas, United States
Danville Regional Medical Center
馃嚭馃嚫Danville, Virginia, United States